Seres Therapeutics, Inc. (MCRB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on April 21, 2025. The report details a corporate action regarding the Company's capital structure, specifically a reverse stock split of its common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of a reverse stock split.
Material Changes
- Reverse Stock Split: Effective April 21, 2025, at 5:00 p.m. Eastern Time, the Company implemented a 1-for-20 reverse stock split.
- Share Conversion: Every 20 shares of Common Stock issued and outstanding prior to the effective time were automatically converted into one validly issued, fully-paid, and non-assessable share.
- Trading Adjustments: Trading on The Nasdaq Global Select Market began on a split-adjusted basis on April 22, 2025, under the existing symbol "MCRB".
- Identification: The new CUSIP number for the Common Stock is 81750R 201.
- Fractional Shares: No fractional shares were issued; holders entitled to fractional shares received a cash payment in lieu thereof.
- Authorized Shares: The number of authorized shares and the par value ($0.001) remained unchanged.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the trading of the stock on a split-adjusted basis and the impact of the reverse stock split. Management notes that actual results may differ materially due to risks and uncertainties, referencing the "Risk Factors" section of the Company's Annual Report on Form 10-K filed on March 13, 2025. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the new CUSIP number (81750R 201) for trading and settlement purposes.
- Confirm the adjusted share count in brokerage accounts following the 1-for-20 conversion.
- Review the cash payment received, if applicable, for any fractional shares that were not issued.
- Check the Company's Form 10-K (filed March 13, 2025) for updated risk factors and financial context.